Medicus Pharma Announces Closing of $4.25 Million CEO-Led Equity Financings and $10.5 Million Debt Exchange

On November 16, 2026 Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision-guided, biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, reported the closing of an aggregate of $4.25 million fixed-price equity financings priced at-the-market, including a private placement led by its Chief Executive Officer and other insiders. The private placement totaled $1.25 million, or approximately 30% of the total financings, and was made to a limited number of accredited investors consisting primarily of directors and officers of the Company, including $750,000 from Medicus’ Executive Chairman and Chief Executive Officer. Approximately $3.0 million of the financing was conducted via a registered direct offering pursuant to the Company’s shelf registration statement on Form S-3 and a prospectus supplement. The investment reflects management’s and insiders’ support for the Company’s strategic direction, with CD228V, its investigational antibody-drug conjugate utilizing an established Vedotin platform, at the center of its precision oncology focus.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company also announced the exchange of $10.5 million of indebtedness held by Streeterville Capital, LLC ("Streeterville") for preferred shares. Together with the $4.25 million equity financings, and an additional approximately $350,000 of common shares sold via Medicus’ at-the-market program since September 30, 2026, the Company believes that the transactions have strengthened the Company’s shareholders’ equity above Nasdaq’s $2.5 million continued-listing threshold, and that, subject to Nasdaq confirmation, the Company has regained compliance in respect of Nasdaq rule 5550(b).

Maxim Group LLC acted as financial advisor to the Company in connection with the registered direct offering.

CEO-Led Equity Financing and Strategic Alignment

The $4.25 million fixed-price equity financing priced at-the-market includes $1.25 million of participation led by Company insiders, of which $750,000 is attributable to the CEO. The financing is intended to provide additional working capital to support the Company’s operating and development priorities, including the advancement of CD228V, and may also include the strengthening of the Company’s balance sheet through debt repayment. The Company views this insider participation as a demonstration of alignment with shareholders and conviction in its precision oncology-led direction. The registered direct offering was for 97,973 common shares plus pre-funded warrants to purchase up to 1,646,213 common shares, priced at-the-market at an effective price of $1.72 per share and the private placement was for 726,730 common shares, also priced at-the-market at $1.72 per share. The common shares issued in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), and are restricted securities.

Certain directors and senior officers of the Company (collectively, the "Related Parties") purchased an aggregate of 616,272 common shares pursuant to the private placement (the "Related Party Participation"). Participation by the Related Parties in the private placement was considered a "related party transaction" pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company was exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with the Related Party Participation pursuant to sections 5.5(a) and 5.7(1)(a) of MI 61-101, respectively, as neither the fair market value of any securities issued to, nor the consideration paid by, the Related Parties exceeded 25% of the Company’s market capitalization (as defined in MI 61-101). The Company did not file a material change report relating to the Related Party Participation more than 21 days before the expected closing date of the private placement as the details of the Related Party Participation were not settled at such time and the Company wished to close the private placement on an expedited basis for sound business reasons.

Streeterville Debt Exchange and Shareholders’ Equity

Streeterville exchanged $10.5 million of outstanding indebtedness under the Company’s Secured Promissory Notes for 105,000 preferred shares at an issue price of $100 per share. The preferred shares are non-voting, except as required by law, and non-convertible into common shares. They carry an 8% cumulative annual dividend payable in kind and are redeemable at the Company’s option, with no holder redemption right. The exchange did not generate cash proceeds; any indebtedness not exchanged remains outstanding.

Early Warning Disclosure

In connection with the private placement, Dr. Raza Bokhari, company’s Executive Chairman and CEO acquired beneficial ownership of, or control or direction over, an aggregate of 436,046 common shares of the Company indirectly through RBx Capital LP, an entity controlled by Dr. Bokhari.

Prior to the completion of the transactions described herein, Dr. Bokhari had beneficial ownership of, or control or direction over, directly or indirectly, an aggregate of 74,687 common shares of the Company and stock options exercisable within 60 days to acquire an additional 27,500 common shares, representing approximately 3.8% of the issued and outstanding common shares on a non-diluted basis and approximately 5.1% of the issued and outstanding common shares on a partially diluted basis. Following the transactions described herein, Dr. Raza Bokhari has beneficial ownership of, or control or direction over, directly or indirectly, an aggregate of 510,733 common shares of the Company and stock options exercisable within 60 days to acquire an additional 27,500 common shares, representing approximately 18.3% of the issued and outstanding common shares on a non-diluted basis and approximately 19.1% of the issued and outstanding common shares on a partially diluted basis.

Dr. Bokhari acquired the common shares for investment purposes. Dr. Bokhari may seek to increase or decrease his investment, directly or indirectly in the Company through the market, privately or otherwise, depending on market conditions or any other relevant factors, or may in the future develop plans or intentions relating to any of the other actions listed in (a) through (k) of Form 62-103F1 – Required Disclosure Under the Early Warning Requirements.

Dr. Bokhari’s business address is 300 Conshohocken State Road, Suite 200, West Conshohocken, PA 19428, United States.

For the purposes of this news release and early warning disclosure, the pro forma number and percentage of outstanding common shares owned and controlled by Dr. Bokhari following completion of the transactions described herein is based on 2,788,106 outstanding common shares following the completion of the private placement and the registered direct offering.

This portion of this news release is being issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues. An early warning report will be filed by Dr. Bokhari on SEDAR+ (www.sedarplus.ca) under the Company’s issuer profile. Persons who wish to obtain a copy of the early warning report to be filed by Dr. Bokhari may obtain a copy of such report from SEDAR+ (www.sedarplus.ca) or by contacting Carolyn Bonner, President and CFO of the Company at (610) 636-0184 or [email protected].

(Press release, Medicus Pharma, NOV 16, 2026, View Source [SID1234674794])

Cypherpunk Technologies Reports Third Quarter 2026 Financial Results

On November 16, 2026 Cypherpunk Technologies Inc. (Nasdaq: CYPH) ("Cypherpunk"), a privacy technology company, reported financial results for the third quarter ended September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The launch of Cypherpunk Mining in August was transformative, as it enabled the production of ZEC alongside our purchases and contributes to the security of the Zcash network. In the first six weeks of operation, our fleet earned 8,967.29 ZEC as a result of an exceptional 95% uptime, all of which was added to our treasury in a momentous third quarter for the company," said Douglas E. Onsi, President and Chief Executive Officer of Cypherpunk Technologies. "As we hold the ZEC we mine, we translated our Zcash flow into $9.9 million in recorded revenue. The average fair value of the mined ZEC was more than $1,100, while our hosting cost to mine one ZEC was approximately $104."

"The quarter marked a major milestone for Cypherpunk, and we are already planning for significant continued growth. We intend to increase our overall hashrate through additional equipment purchases with the goal of representing approximately 25% of the total Zcash network over time," said Will McEvoy, Chief Investment Officer of Cypherpunk. "Cypherpunk Mining is the newest piece of the constellation of privacy technologies and investments that we are assembling. With 341,858.75 ZEC held, representing 2.01% of the total circulating supply, we continue to execute on our objective of holding at least 5% of the ZEC supply over time. We also plan to expand our efforts in privacy technology development and investment more broadly as we head into 2027."

Cypherpunk Highlights:

Launched Cypherpunk Mining, the world’s largest Zcash mining fleet at launch

On August 17, 2026, Cypherpunk Mining acquired from Moria Mining, LLC, an affiliate of Winklevoss Treasury Investments, LLC ("WTI"), Bitmain Antminer Z15 Pro Zcash mining machines, the colocation and hosting agreements under which those machines are installed and operated at three third-party hosting facilities, and related hosting deposits (the "Mining Asset Acquisition"). The purchase price of $33.33 million was paid through the issuance to WTI of a pre-funded warrant to purchase 43,290,042 shares of Cypherpunk common stock at an exercise price of $0.001 per share.
Cypherpunk’s mining fleet launched on August 18, 2026, and at the time was the largest Zcash mining operation in the world. Cypherpunk’s fleet has a deployed hashrate of approximately 4.2 GSol/s. At the closing of the Mining Asset Acquisition, Cypherpunk’s fleet represented approximately 18% of total Zcash network hashrate. Cypherpunk’s mining business is led by Kevin Zhang, its Head of Mining, who joined the Company in August 2026.
Key operating metrics

Mining revenue was $9.9 million for the three months ended September 30, 2026, Cypherpunk’s first period of mining operations, and reflects 8,967.29 ZEC earned from August 18, 2026 through September 30, 2026, at an average fair value of $1,105.46 per ZEC.
Fleet operations demonstrated approximately 95% uptime.
Total Zcash network hashrate increased from approximately 23 GSol/s at August 18, 2026 to approximately 32 GSol/s as of November 13, 2026. Cypherpunk’s share of network hashrate represents approximately 13.1% as of November 13, 2026.
Cost to mine one ZEC, excluding depreciation of mining equipment, was $104.33, or 9.44% of the production value of one ZEC mined. Cost to mine one ZEC, including depreciation of mining equipment, was $237.46, or 21.48% of the production value of one ZEC mined.
Positioning the fleet to grow with the network

To expand the mining fleet, in September 2026, Cypherpunk Mining entered into a letter of intent with Bitmain Technologies Delaware Limited ("Bitmain") for the purchase of Bitmain’s next-generation Zcash mining machines with a total purchase commitment of up to $30.0 million, of which $6.0 million was paid as a refundable deposit, with delivery expected in mid-2027. Completion of this transaction would expand Cypherpunk’s mining fleet towards the goal of representing approximately 25% of the overall Zcash network hashrate as that hashrate increases over the next year.
October mining results of 5,721.35 ZEC

In October 2026, Cypherpunk mined an additional 5,721.35 ZEC, all of which were added to the treasury, and achieved an uptime of approximately 97%.
ZEC treasury holdings increased to 341,858.75 ZEC

Since the end of the third quarter, Cypherpunk acquired an additional 3,775.72 ZEC through open market purchases for approximately $3.475 million at an average price of $920.40 per ZEC.
Including the recent open market purchases and the October mining results, Cypherpunk holds a total of 341,858.75 ZEC, representing approximately 2.01% of the circulating supply of ZEC. Cypherpunk’s current stated objective is to accumulate holdings representing at least 5% of the circulating supply of ZEC over time.
Amanda Fabiano appointed to Board of Directors

In September 2026, Cypherpunk appointed Amanda Fabiano to its Board of Directors. Fabiano currently serves as Chief Operating Officer of Nakamoto Inc., a publicly listed bitcoin-focused company, and as an independent director of TeraWulf Inc., a public bitcoin mining company that has expanded into AI and high-performance computing infrastructure. Previously, she held senior mining and investment roles at Galaxy and Fidelity.
Leap Therapeutics Subsidiary Highlights:

Following publication of the randomized Phase 2 DeFianCe study in Clinical Cancer Research in August 2026, receipt of Fast Track designation in May 2026, and alignment with the FDA on the design of a registrational Phase 3 trial in a DKK1-high 2L CRC population, Leap initiated a strategic process to identify the best path forward for sirexatamab and to secure the resources required to advance the program into Phase 3 development. The process may include financing the program as an independent entity or a strategic transaction with a pharmaceutical or biotechnology company, including a partnership, license, collaboration, sale or other business combination. There can be no assurance that the process will result in any transaction or financing, and the Company has not set a timetable for its conclusion.
Third Quarter 2026 Financial Results:

Cypherpunk recorded net income of $306.0 million, or $1.44 per basic share and $1.13 per diluted share, for the three months ended September 30, 2026, compared to a net loss of $3.3 million, or $0.08 per basic and diluted share, for the three months ended September 30, 2025. Cypherpunk’s net income for the 2026 period was primarily driven by the non-cash unrealized gain on the embedded derivative, reflecting the increase in the price of ZEC from $400.09 per ZEC at June 30, 2026 to $1,414.56 per ZEC at September 30, 2026, partially offset by a provision for income taxes of $27.5 million.

Mining revenue was $9.9 million for the three months ended September 30, 2026, Cypherpunk’s first period of mining operations, and reflects 8,967.29 ZEC earned from August 18, 2026 through September 30, 2026 at an average fair value of $1,105.46 per ZEC. Cypherpunk had no revenue in the three months ended September 30, 2025. Mining revenue is a non-cash item, as Cypherpunk received ZEC, not cash.

Cost of revenue (excluding depreciation and amortization) was $0.9 million for the three months ended September 30, 2026 and consisted of hosting costs, including electricity pass-through charges.

Depreciation expense related to Cypherpunk’s mining equipment was $1.2 million for the three months ended September 30, 2026, representing 44 days of depreciation of the mining machines that were acquired in the Mining Asset Acquisition on a straight-line basis over an estimated useful life of three (3) years.

Research and development expenses were $0.2 million for the three months ended September 30, 2026, compared to $1.2 million for the three months ended September 30, 2025. The decrease of $1.0 million in research and development expenses during the three months ended September 30, 2026 as compared to the same period in 2025, was primarily due to a decrease in headcount, clinical trial, and manufacturing costs, due to the completion of the Company’s clinical trials in 2025.

General and administrative expenses were $4.9 million for the three months ended September 30, 2026 compared to $1.9 million for the three months ended September 30, 2025. The increase of $3.0 million in general and administrative expenses during the three months ended September 30, 2026 was primarily due to a $2.2 million increase in stock-based compensation expense. There was also an increase of $0.4 million in professional fees and an increase in insurance costs of $0.4 million.

During the three months ended September 30, 2026, Cypherpunk recorded an unrealized gain of $330.8 million on the change in fair value of embedded derivative, reflecting the increase in the price of ZEC from $400.09 per ZEC at June 30, 2026 to $1,414.56 per ZEC at September 30, 2026.

As of September 30, 2026, Cypherpunk had cash and cash equivalents of $56.0 million and ZEC treasury holdings categorized as a digital asset receivable valued at $470.1 million.

(Press release, Cypherpunk Technologies, NOV 16, 2026, View Source [SID1234674819])

Biocon Gets U.S. FDA Approval for Pebrilzo™ (pertuzumab-qcay) Injection, a Biosimilar to Perjeta®, Expanding Its Oncology Portfolio

On November 16, 2026 Biocon Limited (BSE: 532523; NSE: BIOCON), an innovation‑led global biopharmaceutical company, reported that the U.S. Food and Drug Administration (FDA) has approved Pebrilzo (pertuzumab-qcay), a biosimilar of the reference product Perjeta (pertuzumab). PEBRILZO is a monoclonal antibody used to treat HER2-positive breast cancer by blocking HER2 receptors on cancer cells. The FDA approval further strengthens Biocon’s oncology portfolio.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Shreehas Tambe, CEO & Managing Director, Biocon Limited, said, "The U.S. FDA approval of PEBRILZO, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. For patients diagnosed with HER2-positive breast cancer, the burden of the disease extends well beyond the physical challenges, often placing considerable financial strain on patients and their families. As our fifth oncology biosimilar to receive U.S. FDA approval, PEBRILZO strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines."

In September, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had given a positive opinion recommending the granting of a marketing authorization for Biocon’s Pertuzumab biosimilar as 420 mg/14 mL concentrate solution for infusion, under the brand name Pebrilzo, for the treatment of HER2‑positive breast cancer across multiple disease stages in Europe.

Biocon also announced a global settlement and license agreement with Genentech securing the earliest licensed launch date for PEBRILZO in the United States in Q3 of calendar year 2028.

Biocon’s Oncology Portfolio and Pipeline:

Biocon’s oncology strategy combines an established portfolio with continued development across additional treatment approaches. PEBRILZO will join its robust portfolio of oncology therapies, which includes Ogivri (trastuzumab-dkst), Jobevne (bevacizumab-nwgd), Fulphila (pegfilgrastim-jmdb), and Aukelso (denosumab-kyqq). Building on this foundation, Biocon’s growing oncology pipeline includes proposed biosimilars to trastuzumab/hyaluronidase, nivolumab and pembrolizumab, spanning HER2-directed therapy and immuno-oncology.

About HER2-Positive Breast Cancer:

HER2-positive breast cancer is a subtype of breast cancer characterized by HER2 protein overexpression and/or HER2 gene amplification, which drives aggressive tumor growth.

Approximately 320,000 women in the United States are expected to be diagnosed with breast cancer in 2026.1 Of those diagnoses, about 20% will be HER2-positive breast cancer2. On a broader scale, 1 in 8 women are expected to be diagnosed with breast cancer during her lifetime, highlighting the ongoing need for treatment options in this area2.

About PEBRILZO (pertuzumab-qcay)

The approval for PEBRILZO (pertuzumab-qcay) was based on a comprehensive package containing structural and functional analytical characterization, analytical similarity, and comparative clinical pharmacokinetic data, which confirmed that PEBRILZO is highly similar to the reference biologics, Perjeta with no clinically meaningful differences in quality, safety, efficacy, and immunogenicity.

WARNING

LEFT VENTRICULAR DYSFUNCTION and EMBRYO-FETAL TOXICITY

Left Ventricular Dysfunction: PEBRILZO can cause subclinical and clinical cardiac failure manifesting as decreased LVEF and CHF. Evaluate cardiac function prior to and during treatment. Discontinue PEBRILZO treatment for a confirmed clinically significant decrease in left ventricular function.
Embryo-fetal Toxicity: Exposure to PEBRILZO can cause embryo-fetal death and birth defects. Advise patients of these risks and the need for effective contraception.
INDICATIONS

PEBRILZO is a HER2/neu receptor antagonist indicated for:

Metastatic Breast Cancer (MBC): PEBRILZO is indicated for use in combination with trastuzumab and docetaxel for the treatment of adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
Early Breast Cancer (EBC): PEBRILZO is indicated for use in combination with trastuzumab and chemotherapy for:
the neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early-stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer.
the adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence.
CONTRAINDICATIONS

PEBRILZO is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients.

WARNINGS AND PRECAUTIONS

Left Ventricular Dysfunction

Pertuzumab can cause left ventricular dysfunction, including symptomatic heart failure. Decreases in LVEF have been reported with drugs that block HER2 activity, including PEBRILZO.
Assess LVEF prior to initiation of PEBRILZO and at regular intervals during treatment to ensure that LVEF is within normal limits. If the LVEF declines and has not improved, or has declined further at the subsequent assessment, consider permanent discontinuation of PEBRILZO and trastuzumab.
In the pertuzumab-treated patients with MBC in CLEOPATRA, left ventricular dysfunction occurred in 4% of patients and symptomatic left ventricular systolic dysfunction (LVSD) (congestive heart failure) occurred in 1% of patients. Patients who received prior anthracyclines or prior radiotherapy to the chest area may be at higher risk of decreased LVEF or left ventricular dysfunction.
In patients receiving pertuzumab as a neoadjuvant treatment in combination with trastuzumab and docetaxel in NeoSphere, LVEF decline > 10% and a drop to < 50% occurred in 8% of patients and left ventricular dysfunction occurred in 3% of patients. LVEF recovered to ≥ 50% in all these patients.
In patients receiving neoadjuvant pertuzumab in TRYPHAENA, LVEF decline > 10% and a drop to < 50% occurred in 7% of patients treated with pertuzumab plus trastuzumab and FEC followed by pertuzumab plus trastuzumab and docetaxel, 16% of patients treated with pertuzumab plus trastuzumab and docetaxel following FEC, and 11% of patients treated with pertuzumab in combination with TCH. Left ventricular dysfunction occurred in 6% of patients treated with pertuzumab plus trastuzumab and FEC followed by pertuzumab plus trastuzumab and docetaxel, 4% of patients treated with pertuzumab plus trastuzumab and docetaxel following FEC, and 3% of patients treated with pertuzumab in combination with TCH. Symptomatic LVSD occurred in 4% of patients treated with pertuzumab plus trastuzumab and docetaxel following FEC, 1% of patients treated with pertuzumab in combination with TCH, and none of the patients treated with pertuzumab plus trastuzumab and FEC followed by pertuzumab plus trastuzumab and docetaxel. LVEF recovered to ≥ 50% in all but one patient.
In patients receiving neoadjuvant pertuzumab in BERENICE, in the neoadjuvant period, LVEF decline ≥ 10% and a drop to < 50% as measured by ECHO/MUGA assessment occurred in 7% of patients treated with pertuzumab plus trastuzumab and paclitaxel following ddAC, and 2% of patients treated with pertuzumab plus trastuzumab and docetaxel following FEC. Ejection fraction decreased (asymptomatic LVD) occurred in 7% of patients treated with pertuzumab plus trastuzumab and paclitaxel following ddAC and 4% of the patients treated with pertuzumab plus trastuzumab and docetaxel following FEC in the neoadjuvant period. Symptomatic LVSD (NYHA Class III/IV Congestive Heart Failure) occurred in 2% of patients treated with pertuzumab plus trastuzumab and paclitaxel following ddAC and none of the patients treated with pertuzumab plus trastuzumab and docetaxel following FEC in the neoadjuvant period.
In patients receiving adjuvant pertuzumab in APHINITY, the incidence of symptomatic heart failure (NYHA Class III/IV) with a LVEF decline ≥ 10% and a drop to < 50% was 0.6%. Of the patients who experienced symptomatic heart failure, 47% of pertuzumab-treated patients had recovered (defined as 2 consecutive LVEF measurements above 50%) at the data cutoff. The majority of the events (86%) were reported in anthracycline-treated patients. Asymptomatic or mildly symptomatic (NYHA Class II) declines in LVEF ≥ 10% and a drop to < 50% were reported in 3% of pertuzumab-treated patients, of whom 80% recovered at the data cutoff.
Pertuzumab has not been studied in patients with a pretreatment LVEF value of < 50%, a prior history of CHF, decreases in LVEF to < 50% during prior trastuzumab therapy, or conditions that could impair left ventricular function such as uncontrolled hypertension, recent myocardial infarction, serious cardiac arrhythmia requiring treatment or a cumulative prior anthracycline exposure to > 360 mg/m2 of doxorubicin or its equivalent.
Embryo-Fetal Toxicity

Based on its mechanism of action and findings in animal studies, pertuzumab can cause fetal harm when administered to a pregnant woman. Pertuzumab is a HER2/neu receptor antagonist. Cases of oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death have been reported with use of another HER2/neu receptor antagonist (trastuzumab) during pregnancy. In an animal reproduction study, administration of pertuzumab to pregnant cynomolgus monkeys during the period of organogenesis resulted in oligohydramnios, delayed fetal kidney development, and embryo-fetal death at exposures 2.5 to 20 times the exposure in humans at the recommended dose, based on Cmax.
Infusion-Related Reactions

Pertuzumab can cause serious infusion reactions, including fatal events.
In CLEOPATRA, on the first day, when only pertuzumab was administered, infusion-related reactions occurred in 13% of patients and < 1% were Grade 3 or 4. The most common infusion reactions (≥ 1%) were pyrexia, chills, fatigue, headache, asthenia, hypersensitivity, and vomiting. During the second cycle when all drugs were administered on the same day, the most common infusion reactions in the pertuzumab-treated group (≥ 1%) were fatigue, dysgeusia, hypersensitivity, myalgia, and vomiting. In APHINITY, when pertuzumab was administered in combination with trastuzumab and chemotherapy on the same day, infusion-related reactions occurred in 21% of patients with <1% of patients experiencing Grade 3-4 events.
Observe patients closely for 60 minutes after the first infusion and for 30 minutes after subsequent infusions of pertuzumab. If a significant infusion-related reaction occurs, slow or interrupt the infusion, and administer appropriate medical therapies. Monitor patients carefully until complete resolution of signs and symptoms. Consider permanent discontinuation in patients with severe infusion reactions.
Hypersensitivity Reactions/Anaphylaxis

Pertuzumab can cause hypersensitivity reactions, including anaphylaxis.
In CLEOPATRA, the overall frequency of hypersensitivity/anaphylaxis reactions was 11% in pertuzumab-treated patients, with Grade 3 – 4 hypersensitivity reactions and anaphylaxis occurring in 2% of patients.
In NeoSphere, TRYPHAENA, BERENICE, and APHINITY, hypersensitivity/anaphylaxis events were consistent with those observed in CLEOPATRA. In APHINITY, the overall frequency of hypersensitivity/anaphylaxis was 5% in the pertuzumab treated group. The incidence was highest in the pertuzumab plus TCH treated group (8%) with 1% Grade 3 – 4 events.
Observe patients closely for hypersensitivity reactions. Severe hypersensitivity, including anaphylaxis and fatal events, have been observed in patients treated with pertuzumab. Angioedema has been described in postmarketing reports. Medications to treat such reactions, as well as emergency equipment, should be available for immediate use prior to administration of pertuzumab. PEBRILZO is contraindicated in patients with known hypersensitivity to pertuzumab or to any of its excipients.
MOST COMMON ADVERSE REACTIONS

Metastatic Breast Cancer

The most common adverse reactions (> 30%) with PEBRILZO in combination with trastuzumab and docetaxel were diarrhea, alopecia, neutropenia, nausea, fatigue, rash, and peripheral neuropathy.
Neoadjuvant Treatment of Breast Cancer

The most common adverse reactions (> 30%) with PEBRILZO in combination with trastuzumab and docetaxel were alopecia, diarrhea, nausea, and neutropenia.
The most common adverse reactions (>30%) with PEBRILZO in combination with trastuzumab and docetaxel when given for 3 cycles following 3 cycles of FEC were fatigue, alopecia, diarrhea, nausea, vomiting, and neutropenia.
The most common adverse reactions (>30%) with PEBRILZO in combination with docetaxel, carboplatin, and trastuzumab (TCH) were fatigue, alopecia, diarrhea, nausea, vomiting, neutropenia, thrombocytopenia, and anemia.
The most common adverse reactions (>30%) with PEBRILZO in combination with trastuzumab and paclitaxel when given for 4 cycles following 4 cycles of ddAC were nausea, diarrhea, alopecia, fatigue, constipation, peripheral neuropathy, and headache.
The most common adverse reactions (>30%) with PEBRILZO in combination with trastuzumab and docetaxel when given for 4 cycles following 4 cycles of FEC were diarrhea, nausea, alopecia, asthenia, constipation, fatigue, mucosal inflammation, vomiting, myalgia, and anemia.
Adjuvant Treatment of Breast Cancer

The most common adverse reactions (>30%) with PEBRILZO in combination with trastuzumab and chemotherapy were diarrhea, nausea, alopecia, fatigue, peripheral neuropathy and vomiting.
Please refer to the full Patient Information for additional Important Safety Information, including BOXED WARNINGS. To report SUSPECTED ADVERSE REACTIONS, contact Biocon at 1-833-986-1468.

(Press release, Biocon, NOV 16, 2026, View Source [SID1234674836])

Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise

On November 16, 2026 Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported that it will host a virtual investor event on Friday, November 20, 2026, at 8:00 a.m. Eastern Time to discuss updated Phase 1 data for ERAS-0015, a potential best-in-class pan-RAS molecular glue for RAS-mutant solid tumors, and other updates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The event will follow an oral presentation of ERAS-0015 clinical data and a poster presentation of nonclinical ERAS-0015 and ERAS-4001 combination data at the 38th EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics, taking place Nov. 18–20 in Barcelona, Spain.

To register, click here. A live question and answer session will follow the formal presentations. A live webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at Erasca.com/events.

About ERAS-0015
ERAS-0015 is an investigational, oral, highly potent pan-RAS molecular glue designed to inhibit RAS signaling with a potential best-in-class profile. Erasca is evaluating ERAS-0015 in the AURORAS-1 Phase 1 trial in patients with RAS-mutant solid tumors. Early dose escalation data in AURORAS-1 demonstrated favorable safety and tolerability results, well-behaved, linear PK, and confirmed and unconfirmed partial responses in multiple patients across multiple tumor types with different RAS mutations, including confirmed partial responses at doses as low as 8 mg once daily (QD). ERAS-0015 is also designed to prevent resistance against mutant-selective inhibitors through inhibition of RAS wildtype variants. In addition, ERAS-0015 has demonstrated favorable absorption, distribution, metabolism, and excretion (ADME) and pharmacokinetic (PK) properties in multiple animal species.

About ERAS-4001
ERAS-4001 is an investigational, oral, highly potent, and selective pan-KRAS inhibitor with a potential first-in-class and best-in-class profile. Erasca is evaluating ERAS-4001 in the BOREALIS-1 Phase 1 trial in patients with KRAS-mutant solid tumors. ERAS-4001 demonstrated favorable preclinical in vitro potency against KRAS G12X mutations as well as KRAS wildtype amplifications, which may limit treatment resistance mediated through KRAS wildtype activation. No activity was observed for ERAS-4001 against HRAS or NRAS wildtype proteins in preclinical studies, which may enable a better therapeutic window compared to pan-RAS inhibitors. ERAS-4001 showed potent activity against both GTP-bound (active state) and GDP-bound (inactive state) KRAS with single digit nanomolar IC50s. In vivo, ERAS-4001 induced tumor regression in multiple KRAS-mutant models. In preclinical studies, ERAS-4001 showed encouraging ADME and PK properties.

(Press release, Erasca, NOV 16, 2026, View Source [SID1234674852])

Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout

On November 16, 2026 Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), reported the financial results for the third quarter ended September 30, 2026, and highlighted continued progress across its clinical development programs, including completion of treatment in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin (also known as naxtarubicin) in relapsed or refractory acute myeloid leukemia (AML).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Moleculin continues to advance its lead clinical program following completion of treatment for all 90 patients in Part A of the MIRACLE trial. The Company remains on track to report comprehensive Part A data in the first quarter of 2027. These data are expected to support selection of the optimal Annamycin dose for advancement into Part B, which is currently planned to begin in the first half of 2027.

"We are approaching one of the most important milestones in Moleculin’s development, and I believe our progress has positioned us to enter 2027 with meaningful momentum," said Walter Klemp, Chairman and Chief Executive Officer of Moleculin. "Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement. We are now focused on delivering the comprehensive dataset in the first quarter of 2027, which we expect will provide important insights into Annamycin’s clinical activity, safety and optimal dose for advancement into Part B. We are also looking forward to releasing quantitative market research data soon, further supporting the commercial opportunity for Annamycin "

"What gives us confidence as we approach this readout is the totality of evidence generated to date," continued Mr. Klemp. "We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin’s differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy. We believe Annamycin has the potential to address a meaningful treatment gap in AML, and the upcoming Part A results represent an important opportunity to further evaluate that potential. Our priority is clear: execute on the data readout, make informed development decisions and advance Annamycin toward its next critical milestones."

Recent Highlights

Completed treatment for all 90 patients in Part A of the Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML. The Company remains on track for a comprehensive data readout in the first quarter of 2027. The full Part A dataset is expected to inform optimal dose selection for the planned initiation of Part B.
Published a peer-reviewed analysis in Frontiers in Cardiovascular Medicine evaluating cardiac safety findings from 90 patients treated with Annamycin across five clinical trials in AML and metastatic soft tissue sarcoma. The analysis, independently evaluated by a cardio-oncology laboratory at Cleveland Clinic, found no clinical or subclinical evidence of treatment-related cardiotoxicity, including at cumulative Annamycin exposures exceeding traditional lifetime limits for conventional anthracyclines.
Presented new preclinical data at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Conference on Pancreatic Cancer indicating that Annamycin’s antitumor activity in pancreatic cancer models is partially mediated by CD8+ T cell cytotoxicity. These findings suggest Annamycin may help expose immunologically "cold" tumors to immune attack, potentially supporting combination treatment approaches.
Announced acceptance of data from the MIRACLE trial for presentation at the 2026 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting. The presentation will highlight interim results from the pivotal Phase 2/3 trial in patients with relapsed or refractory AML.
Expected Milestones for the Annamycin Development Program

Q1 2027: MIRACLE – Comprehensive Part A data readout following completion of treatment for all 90 patients
1H 2027: MIRACLE – Planned initiation of Part B following optimal dose selection
1H 2027: Planned initiation of physician-sponsored clinical trial evaluating Annamycin for pancreatic cancer
1H 2028: Planned initiation of third-line relapsed/refractory AML subject trial
1H 2028: Planned initiation of pediatric AML clinical study
2H 2028: Complete recruitment of Part B
2H 2028: Primary efficacy data for MIRACLE 2nd line subjects
2028-2029: Begin a rolling submission of a New Drug Application (NDA) for the treatment of R/R AML for accelerated approval on primary endpoint of CR from MIRACLE
Additional Pipeline Programs

Moleculin continues to support development activities for its WP1066 program through investigator-sponsored research, including a physician-sponsored Phase 1B/2 clinical trial evaluating WP1066 in combination with radiation for the treatment of glioblastoma. These programs complement Moleculin’s primary focus on advancing Annamycin.

Third Quarter 2026 Financial Results

Research and development expenses were approximately $4.5 million for the three months ended September 30, 2026, compared to approximately $3.7 million for the same period in 2025. The increase was primarily attributable to activities related to the MIRACLE clinical trial.

General and administrative expenses were approximately $2.1 million for the three months ended September 30, 2026, compared to approximately $2.1 million for the same period in 2025.

Net loss for the third quarter of 2026 was approximately $6.5 million, compared to approximately $25.4 million for the same period in 2025. The decrease in net loss was primarily attributable to the absence of the approximately $20.6 million non-cash loss on the issuance of warrant liabilities recorded in the prior-year period.

For the nine months ended September 30, 2026, research and development expenses were approximately $15.3 million, compared to approximately $10.8 million for the same period in 2025. The increase was primarily related to the MIRACLE clinical trial, additional nonclinical studies and other research costs. General and administrative expenses were approximately $6.7 million for the nine months ended September 30, 2026, compared to approximately $6.7 million for the same period in 2025.

As of September 30, 2026, Moleculin had cash and cash equivalents of approximately $7.3 million, compared to approximately $8.9 million as of December 31, 2025. Net cash used in operating activities for the nine months ended September 30, 2026 was approximately $21.7 million.

(Press release, Moleculin, NOV 16, 2026, View Source [SID1234674795])